303 related articles for article (PubMed ID: 26343633)
1. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
[TBL] [Abstract][Full Text] [Related]
2. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
5. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression.
Stivers PJ; Harmonay L; Hicks A; Mehmet H; Morris M; Robinson GM; Strack PR; Savage MJ; Zaller DM; Zwierzynski I; Brandish PE
PLoS One; 2015; 10(12):e0145151. PubMed ID: 26670328
[TBL] [Abstract][Full Text] [Related]
7. Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel.
Ding N; Ping L; Shi Y; Feng L; Zheng X; Song Y; Zhu J
Biochem Biophys Res Commun; 2014 Oct; 453(3):392-7. PubMed ID: 25268318
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a compensatory regulation of colonic O-GlcNAc transferase and O-GlcNAcase expression in response to disruption of O-GlcNAc homeostasis.
Decourcelle A; Loison I; Baldini S; Leprince D; Dehennaut V
Biochem Biophys Res Commun; 2020 Jan; 521(1):125-130. PubMed ID: 31630803
[TBL] [Abstract][Full Text] [Related]
9. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.
Yuzwa SA; Shan X; Macauley MS; Clark T; Skorobogatko Y; Vosseller K; Vocadlo DJ
Nat Chem Biol; 2012 Feb; 8(4):393-9. PubMed ID: 22366723
[TBL] [Abstract][Full Text] [Related]
10. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
11. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.
Zuliani I; Lanzillotta C; Tramutola A; Francioso A; Pagnotta S; Barone E; Perluigi M; Di Domenico F
Neurotherapeutics; 2021 Jan; 18(1):340-363. PubMed ID: 33258073
[TBL] [Abstract][Full Text] [Related]
12. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
[TBL] [Abstract][Full Text] [Related]
13. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
Gong CX; Liu F; Iqbal K
Alzheimers Dement; 2016 Oct; 12(10):1078-1089. PubMed ID: 27126545
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
16. O-GlcNAc transferase inhibitors: current tools and future challenges.
Trapannone R; Rafie K; van Aalten DM
Biochem Soc Trans; 2016 Feb; 44(1):88-93. PubMed ID: 26862193
[TBL] [Abstract][Full Text] [Related]
17. A genetic model to study
St Amand MM; Bond MR; Riedy J; Comly M; Shiloach J; Hanover JA
J Biol Chem; 2018 Aug; 293(35):13673-13681. PubMed ID: 29954943
[No Abstract] [Full Text] [Related]
18. Potential role of O-GlcNAcylation and involvement of PI3K/Akt1 pathway in the expression of oncogenic phenotypes of gastric cancer cells in vitro.
Zhang N; Chen X
Biotechnol Appl Biochem; 2016 Nov; 63(6):841-851. PubMed ID: 26333304
[TBL] [Abstract][Full Text] [Related]
19. Ac
Wang H; Guo J; Wang N; Wang J; Xue Q; Wang J; Liu W; Liu K; Cao X; Zhao W; Xi R; Niu Y; Wang P; Li J
Bioorg Med Chem Lett; 2019 Mar; 29(6):802-805. PubMed ID: 30713024
[TBL] [Abstract][Full Text] [Related]
20. Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase.
Konrad RJ; Zhang F; Hale JE; Knierman MD; Becker GW; Kudlow JE
Biochem Biophys Res Commun; 2002 Apr; 293(1):207-12. PubMed ID: 12054585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
